Metrics as of 10/15/2026, 03:51 AM (Berlin time), refresh in progress.
Mirum Pharmaceuticals Stock
Mirum Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Christopher Peetz
- Employees
- 433
- Market cap
- $5.2 B
- IPO
- 18/07/2019
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm based in Foster City, US, dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. The company was founded in 2018 and is listed on the NASDAQ. Its lead experimental drug, LIVMARLI, is an oral treatment…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Mirum Pharmaceuticals stock: price history
1D
+0.4%
1W
-0.8%
1M
-17.4%
6M
-17.1%
YTD
+1.2%
1Y
+9.1%
2Y
+101.1%
5Y
+367.1%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~7% stronger price swings than usual
Ask the agents about Mirum Pharmaceuticals
Analyst assessment of Mirum Pharmaceuticals
PRICE TARGET LOW
US$130.00
CONSENSUS
US$153.20
MEDIAN
US$149.00
PRICE TARGET HIGH
US$200.00
1
STRONG BUY
17
BUY
0
HOLD
0
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 13/10/2026
Mirum Pharmaceuticals stock metrics
P/E
-5.49
P/B
-486.22
EV/EBITDA
-7.24
RETURN ON EQUITY
645.0%
NET MARGIN
-38.1%
DEBT/EQUITY
-72.97
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.8%
FLOAT SHARES
53,791,003
AVG. DAILY VOLUME (30D)
826,057
Insider transactions (SEC)
Peetz Christopher
Peetz Christopher
BJERKHOLT ERIC
BJERKHOLT ERIC
Peetz Christopher
Institutional holders
Comparable stocks
Frequently asked questions about Mirum Pharmaceuticals stock
What does Mirum Pharmaceuticals do?
Mirum Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Christopher Peetz, the company employs around 433 people.
The IPO was on 18/07/2019; the stock trades on NASDAQ under the ticker MIRM.
What do analysts say about Mirum Pharmaceuticals stock?
18 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$153.20, ranging from US$130.00 to US$200.00, with a median of US$149.00.
This is an external assessment, not a statement by Market Jury.
When does Mirum Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does Mirum Pharmaceuticals pay a dividend?
No, Mirum Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Mirum Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Mirum Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Mirum Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.